Anteris Technologies Global Corp. (AVR)

NASDAQ: AVR · Real-Time Price · USD
3.990
-0.390 (-8.90%)
At close: Jun 16, 2025, 4:00 PM
4.010
+0.020 (0.50%)
After-hours: Jun 16, 2025, 4:29 PM EDT
-8.90%
Market Cap 156.72M
Revenue (ttm) 2.49M
Net Income (ttm) -81.81M
Shares Out 36.06M
EPS (ttm) -3.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 186,119
Open 4.400
Previous Close 4.380
Day's Range 3.980 - 4.715
52-Week Range 2.340 - 8.790
Beta 0.74
Analysts Strong Buy
Price Target 16.50 (+313.53%)
Earnings Date May 13, 2025

About AVR

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for s... [Read more]

Sector Healthcare
IPO Date Dec 13, 2024
Employees 136
Stock Exchange NASDAQ
Ticker Symbol AVR
Full Company Profile

Financial Performance

In 2024, AVR's revenue was $2.70 million, a decrease of -1.17% compared to the previous year's $2.74 million. Losses were -$76.29 million, 65.8% more than in 2023.

Financial numbers in USD Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for AVR stock is "Strong Buy." The 12-month stock price forecast is $16.5, which is an increase of 313.53% from the latest price.

Price Target
$16.5
(313.53% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to...

7 days ago - GlobeNewsWire

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris ® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed...

2 months ago - GlobeNewsWire

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year

3 months ago - GlobeNewsWire

Anteris Reports 2024 Financial Results and Provides Corporate Update

EAGAN, Minn. and BRISBANE, Australia, March 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed ...

3 months ago - GlobeNewsWire

Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering

BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC” or “Anteris”) is pleased to announce the closing of its initial public offering of 14,800,000 shares of i...

6 months ago - Business Wire

Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering

BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC”) today announced the pricing of its initial public offering of 14,800,000 shares of its common stock (“Co...

6 months ago - Business Wire

Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering

BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC”) today announced that it has launched the roadshow for its proposed initial public offering of 14,800,000...

6 months ago - Business Wire

Cardiac device maker Anteris Technologies files for $75M IPO

Cardiac device maker Anteris Technologies Global (AVR) has filed to raise $75M through a U.S. initial public offering.

7 months ago - Seeking Alpha

Australian medical device company Anteris Technologies Global files for a $75 million US IPO

Anteris Technologies Global, an Australia-based maker of artificial heart valves, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The company's shares are curren...

7 months ago - Renaissance Capital

Anteris Technologies Global IPO Registration Document (S-1)

Anteris Technologies Global has filed to go public with an IPO on the NASDAQ.

7 months ago - SEC.gov